MARKET

EBS

EBS

Emergent Biosolutions Inc
NYSE
2.530
+0.130
+5.42%
Pre Market: 2.560 +0.03 +1.19% 04:54 12/07 EST
OPEN
2.400
PREV CLOSE
2.400
HIGH
2.660
LOW
2.360
VOLUME
10
TURNOVER
0
52 WEEK HIGH
16.66
52 WEEK LOW
1.810
MARKET CAP
131.07M
P/E (TTM)
-0.2094
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at EBS last week (1127-1201)?
Weekly Report · 3d ago
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
NASDAQ · 11/29 16:56
What's Going On With Emergent Biosolutions Stock?
Emergent biosolutions received a $75 million contract option from the biomedical advanced research and development authority. The company will acquire newly licensed anthrax vaccine cyfendus. Deliveries of the vaccine are expected to begin in 2023 and be completed in 2024. The vaccine was approved by the fda in july.
Benzinga · 11/28 15:11
Emergent Biosolutions Inc: Current report
Press release · 11/28 15:08
Emergent Biosolutions wins $75 million contract option from BARDA
Emergent biosolutions wins $75 million contract option from barda for the acquisition of newly licensed anthrax vaccine cyfendus. Deliveries are expected to begin this calendar year and be complete by the end of 2024. Emergent biosolutions says it received a $75m contract option.
Seeking Alpha · 11/28 12:14
The Biomedical Advanced Research And Development Authority Has Awarded A $75M Option To Emergent Biosolutions' Existing Contract For The Acquisition Of Newly Licensed Anthrax Vaccine Cyfendus
Benzinga · 11/28 12:04
Weekly Report: what happened at EBS last week (1120-1124)?
Weekly Report · 11/27 09:16
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower
Jp morgan bullish on six big biotechs, rates nine others neutral or lower. Insmed, denali, immunocore, crinetics, mirum and biocryst among those rated overweight. Investment bank was less keen on cervel therapeutics, alkermes and esperion.
Seeking Alpha · 11/25 21:32
More
About EBS
Emergent BioSolutions, Inc. is a life sciences company providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). Its segments include Products Segment and Services Segment. The Products Segment includes the government-medical countermeasures (MCM) business, which focuses on procurement of MCM products and procured product candidates by domestic and international government customers. It sells MCM products and procures product candidates to domestic and international non-government organizations and to governments outside of the United States. It also includes the commercial business, which focuses on sales of NARCAN (naloxone HCI) Nasal Spray and its travelers' vaccines. The Services Segment consists of contract development and manufacturing (CDMO) services, which includes development services (process and analytical development), drug substance manufacturing and drug product manufacturing (fill/finish).

Webull offers Emergent Biosolutions Inc stock information, including NYSE: EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.